Related Experiment Video
Updated: Jun 6, 2025
Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
Published on: February 15, 2022
C3 Glomerulopathy: A Current Perspective in an Evolving Landscape
Eric Keoni Magliulo1, Prasanth Ravipati1
1Division of Nephrology, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA.
Insights
Complement 3 (C3) glomerulopathy (C3G) is a kidney disease often leading to end-stage kidney disease. Identifying distinct causes of C3G is crucial for developing targeted therapies beyond current ineffective treatments.
Area of Science:
- Nephrology
- Immunology
- Complement System Biology
Background:
- Complement 3 (C3) glomerulopathy (C3G) is a kidney disease driven by complement alternative pathway dysregulation.
- C3G has a high progression rate to end-stage kidney disease (50% within 10 years).
- Current treatments for C3G are largely nonspecific immune suppression with limited efficacy.
Purpose of the Study:
- To review the current classification, evaluation, and treatment landscape of C3G.
- To highlight the challenges in managing C3G.
- To emphasize the need for etiology-specific treatments.
Main Methods:
- Literature review of C3G classification, diagnosis, and therapeutic strategies.
- Analysis of current understanding of C3G pathogenesis.
- Synthesis of recent advances in complement-targeted therapies.
Main Results:
- C3G is categorized into four main groups: genetic, autoimmune, monoclonal immunoglobulin-associated, and idiopathic.
- Advances in understanding complement dysregulation are paving the way for targeted therapies.
- Novel complement-targeted therapies offer potential for improved outcomes.
Conclusions:
- Accurate classification of C3G based on underlying etiology is essential.
- Targeted therapies directed at specific C3G causes show promise for improving patient outcomes.
- Further research into distinct C3G subtypes is needed to optimize treatment strategies.
Background:
Complement 3 (C3) glomerulopathy (C3G) is a heterogenous disease characterized by dysregulation of the complement alternative pathway. Within 10 years of a diagnosis, roughly 50% of patients with C3G will progress to end-stage kidney disease. Historically, treatment options have been limited to nonspecific immune suppression with suboptimal response rates to recommended therapies. Advances in immunology and the emergence of novel complement-targeted therapies have shifted the focus toward identifying the distinct underlying etiologies of C3G.
Summary:
In this review, we provide a description of the current landscape and challenges faced in the classification, evaluation, and treatment of patients with C3G.
Key Message:
C3G can be broadly separated into four distinct groups: (1) genetic mutations/variants, (2) autoimmune/acquired autoantibodies, (3) monoclonal immunoglobulin-associated C3G, and (4) C3G without an identified cause. Therapy directed toward the underlying pathogenetic cause of C3G may improve outcomes in a disease in which current treatment options are largely ineffective.
More Related Videos
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
12:48In Vivo Dynamics of Retinal Microglial Activation During Neurodegeneration: Confocal Ophthalmoscopic Imaging and Cell Morphometry in Mouse Glaucoma
Published on: May 11, 2015
Related Concept Videos
01:25Glaucoma: Overview
01:27Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
01:28Angle Closure Glaucoma: Treatment
01:20Renal Corpuscle
Glomerulus: Structure and Function
The glomerulus is a tiny, intricate network of capillaries located at the beginning of the nephron. It's enveloped by the Bowman's capsule and receives its blood supply from an afferent arteriole, which divides into numerous...